NYSE:LLY 26 November 2025 - 10 December 2025

Updated: December 8, 2025 – For informational purposes only, not investment advice. As U.S. markets trade on Monday, Eli Lilly and Company is changing hands near $1,010 per share, roughly flat versus Friday’s close around $1,010.31 and modestly below late‑November highs near $1,110.TechStock²

On Friday, November 28, 2025, Eli Lilly and Company shares traded lower, giving back a slice of recent gains after the drugmaker became the first pharmaceutical company ever to hit a $1 trillion market valuation on November 21.Reuters As of late morning in New York, Lilly stock was changing hands at around $1,075–$1,080 per share, down roughly 2.5% on the day. That still leaves the stock more than 70% above its 52‑week low of $623.78 and only about 3% below its record high of $1,111.99.StockAnalysis

As U.S. markets prepare for a shortened Black Friday session on Friday, November 28, 2025, Eli Lilly and Company will open trading as one of the most closely watched stocks on Wall Street. The drugmaker has just joined the exclusive $1 trillion market‑cap club thanks to explosive demand for its GLP‑1 weight‑loss and diabetes drugs, alongside new momentum in Alzheimer’s disease and oncology. At last trade, Lilly shares were around $1,104 with a market capitalization near $990 billion, giving the company a trailing P/E ratio of roughly 54x earnings and a forward P/E in the mid‑30s—valuations that remain elevated even after a modest pullback from the trillion‑dollar peak. Yahoo Finance+1

Eli Lilly and Company is having another headline‑heavy session on Wednesday, November 26, 2025, as investors digest its new status as the first trillion‑dollar healthcare company, fresh moves on obesity‑drug pricing, and growing chatter about a potential stock split. Reuters+1 As of mid‑afternoon trading, Eli Lilly stock is changing hands around $1,105 per share, down roughly 0.4% on the day, after touching an intraday high above $1,117. That still leaves its market value just over $1 trillion, following a more than 35% rally year to date driven by explosive demand for its GLP‑1 weight‑loss and diabetes drugs Zepbound and Mounjaro. Reuters